查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929582

GalNAc寡核苷酸偶联物市场按产品类型、治疗应用、给药途径、最终用户和分销管道划分，全球预测，2026-2032年

GalNAc-Oligonucleotide Conjugates Market by Product Type, Therapeutic Application, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 Galnac-寡核苷酸偶联物市场价值为 4.1637 亿美元，预计到 2026 年将成长至 4.5435 亿美元，预计到 2032 年将达到 6.8584 亿美元，复合年增长率为 7.38%。

关键市场统计数据
基准年 2025 4.1637亿美元
预计年份：2026年 4.5435亿美元
预测年份 2032 6.8584亿美元
复合年增长率 (%) 7.38%

本文对 GalNAc-寡核苷酸偶联物的生物学特性、临床应用进展以及指导其治疗应用的不断发展的研发生态系统进行了简明扼要的概述。

GalNAc-寡核苷酸偶联物已成为靶向核酸疗法领域的一项突破性进展，它将配体介导的肝细胞递送与寡核苷酸的治疗多样性相结合。此技术的核心是一种三臂N-乙酰半乳糖胺配体，它能与肝细胞上的去唾液酸糖蛋白受体结合，并将治疗性寡核苷酸选择性地转运至肝臟。这种机制显着提高了肝臟标靶治疗方法的疗效和耐受性，改变了给药模式，并扩大了RNA治疗方法的治疗窗口。

化学、临床策略和商业性合作的最新趋势如何重塑治疗性 GalNAc-寡核苷酸偶联物的开发和应用路径

随着技术、临床和商业性因素的融合，GalNAc-寡核苷酸疗法领域正经历着变革性的转变。偶联化学和连接子设计的突破性进展，使得肝臟标靶性得以逐步提高，剂量得以降低，给药间隔得以延长，同时也改变了药物经济学格局。同时，寡核苷酸稳定性的提升和化学修饰策略的改进，降低了脱靶效应和免疫抗原性，使研发人员能够针对那些未被满足的更高需求和对长期给药耐受性更高的适应症进行研究。

评估2025年关税政策变化如何影响寡核苷酸疗法的采购决策、供应链韧性和生产本地化策略

2025年的政策和贸易环境以新的关税措施和贸易紧张局势为特征，这将对复杂的医药价值链产生连锁反应，包括支持GalNAc-寡核苷酸偶联物的生态系统。影响化学中间体、特殊试剂和某些设备的关税调整可能会增加依赖全球采购原料的研发商和契约製造的投入成本和复杂性。这些发展将增加国际采购的行政负担，并促使采购团队重新评估其供应商风险状况。

将治疗方式类型、治疗用途、给药策略、最终用户和分销管道与商业性和研发重点连结起来的細項分析

细分市场洞察揭示了科学机会与商业性价值在治疗方式、适应症、给药途径、最终用户和分销管道等因素交汇之处。根据产品类型，该领域涵盖反义寡核苷酸、适配体、 微型RNA标靶分子和小干扰RNA（siRNA），每种产品都具有独特的作用机制、研发风险和临床定位考量。反义寡核苷酸疗法能够以成熟的安全性途径实现高效的靶点敲低，而siRNA构建体通常利用GalNAc实现高效的肝臟基因定序，适配体则提供了以独特药物动力学特征实现精准靶向结合的机会。

影响临床开发路径、生产决策和市场进入策略的区域趋势在美洲、欧洲、中东和非洲以及亚太地区各不相同。

区域趋势正在影响 GalNAc-寡核苷酸偶联物创新从发现到临床应用和商业化的进程。在美洲，强大的创业融资机制、深厚的生物技术和合约开发能力网络以及先进的医保报销体系，为快速的临床转化和早期商业化创造了有利环境。肝病领域的临床试验网络和卓越中心能够针对复杂的终点指标进行高效的患者招募，而与当地製造商的合作则为后期项目的可扩展供应链提供了支持。

创新者、製药公司、合约研发生产机构 (CDMO)、特种化学品供应商和诊断合作伙伴如何合作，加速产品开发和商业化

GalNAc寡核苷酸生态系统中的公司围绕着各自独特的策略角色而组织，这些角色决定了它们的竞争优势和成长轨迹。创新生物技术公司专注于独特的序列、专有的偶联化学以及针对特定适应症的临床策略。同时，大型製药公司通常提供后期开发的专业知识、监管指导、全球商业化基础设施以及规模化生产能力。合约受託研究机构(CRO) 和合约开发与生产组织 (CDMO) 作为关键支援机构，提供专业的合成、偶联服务、分析开发以及填充和包装能力，从而降低申办方的时间轴风险。

产业领导者可以采取哪些具体的营运和策略步骤来降低研发风险、优化供应链并加速监管和商业化准备？

产业领导者可以采取切实可行的措施来降低营运风险，加快价值实现速度，同时巩固其竞争优势。首先，儘早与策略性CDMO合作伙伴就製程转移、分析方法开发和监管要求展开合作，可以减少开发过程中的摩擦，避免后期规模化生产阶段出现代价高昂的延误。关于品质指标、变更管理和供应连续性的明确合约条款对于满足临床和商业化进度至关重要。其次，关键原料来源多元化，结合紧急时应对计画和情境建模，可以降低贸易中断和关税相关成本增加所带来的风险。

研究采用混合方法研究途径，结合专家访谈、科学文献综述、监管分析和检验，以确保提供实际可行的见解。

本分析的研究结合了专家的第一手见解和对同行评审文献、监管指导文件以及公开临床试验註册库的全面二手研究，从而构建了一个严谨且多角度的观点。研究人员对价值链上的各相关人员进行了访谈，包括药物化学家、临床开发负责人、生产专家、监管顾问和商业负责人，检验趋势并揭示公开资讯中不常体现的营运细节。这些访谈构成了对供应链风险、发展瓶颈和转化科学挑战进行定性评估的基础。

整合关键技术进步、营运要务和策略重点，这将决定哪些 GalNAc 寡核苷酸计画能够取得临床和商业性成功。

GalNAc-寡核苷酸偶联物代表了标靶核酸疗法的一项重要进展，它结合了受体介导的肝臟传递和分子精准性，可用于治疗多种肝臟和全身性疾病。改进的偶联化学、提高的寡核苷酸稳定性、不断完善的临床试验设计以及成熟的监管互动，为这些治疗方法实现更广泛的治疗应用奠定了基础。然而，将这种潜力转化为永续的商业性成功，需要供应链、临床开发、监管关係和市场进入等各个环节的密切合作。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. GalNAc 寡核苷酸缀合物市场（依产品类型划分）

  • 反义寡核苷酸
  • 适体
  • 微型RNA
  • siRNA

9. GalNAc寡核苷酸偶联物市场依治疗应用划分

  • 感染疾病
  • 代谢性疾病
  • 肿瘤学
  • 罕见疾病

10. GalNAc 寡核苷酸缀合物市场依给药途径划分

  • 静脉注射
  • 皮下注射
    • 临床阶段
    • 临床前阶段

11. GalNAc 寡核苷酸缀合物市场（依最终用户划分）

  • 生技公司
  • 合约研究机构
  • 製药公司
    • 大型製药公司
    • 中小型製药公司

12. GalNAc 寡核苷酸缀合物市场依分销管道划分

  • 直销
  • 经销商
  • 离线
  • 在线的

13. GalNAc 寡核苷酸缀合物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. GalNAc 寡核苷酸缀合物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国 GalNAc 寡核苷酸缀合物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国 GalNAc 寡核苷酸缀合物市场

17. 中国 GalNAc 寡核苷酸缀合物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CureVac NV
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A3806951831

The GalNAc-Oligonucleotide Conjugates Market was valued at USD 416.37 million in 2025 and is projected to grow to USD 454.35 million in 2026, with a CAGR of 7.38%, reaching USD 685.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 416.37 million
Estimated Year [2026] USD 454.35 million
Forecast Year [2032] USD 685.84 million
CAGR (%) 7.38%

A concise foundational overview of GalNAc-oligonucleotide conjugate biology, clinical translation dynamics, and the evolving development ecosystem guiding therapeutic adoption

GalNAc-oligonucleotide conjugates have emerged as a defining advancement in targeted nucleic acid therapeutics, combining ligand-mediated hepatocyte delivery with the therapeutic versatility of oligonucleotides. At the core of this technology is the triantennary N-acetylgalactosamine ligand, which binds the asialoglycoprotein receptor on hepatocytes to selectively transport therapeutic oligonucleotides into the liver. This mechanism has enabled a step change in potency and tolerability for therapies aimed at hepatic targets, shifting dosing paradigms and expanding the therapeutic window for RNA-based modalities.

As the field matures, a broad array of oligonucleotide formats-antisense oligonucleotides, aptamers, microRNA modulators, and small interfering RNAs-are being paired with GalNAc chemistry to enhance cellular uptake and functional activity. The clinical and preclinical pipeline increasingly reflects a focus on metabolic and rare hepatic disorders, while oncology and infectious disease applications probe the limits of targeted delivery and systemic utility. Regulatory experience is accumulating, informing safety monitoring and optimized clinical designs that balance dose, frequency, and route of administration.

Consequently, the ecosystem supporting GalNAc-oligonucleotide development has diversified. Synthetic chemistry firms, contract development and manufacturing organizations, diagnostic and biomarker partners, and clinical research providers now collaborate more closely to translate ligand conjugation advances into clinically meaningful outcomes. This introduction outlines the scientific foundation and commercial context that inform the subsequent sections, providing a framework for understanding technological strengths, clinical opportunities, and strategic imperatives across development and commercialization pathways.

How recent advances in chemistry, clinical strategy, and commercial partnerships are reshaping the development and adoption pathways for therapeutic GalNAc-oligonucleotide conjugates

The landscape for GalNAc-oligonucleotide therapeutics is undergoing transformative shifts driven by converging technological, clinical, and commercial forces. Breakthroughs in conjugation chemistry and linker design have incrementally improved liver targeting, enabling lower doses and extended dosing intervals that alter pharmacoeconomic considerations. At the same time, improvements in oligonucleotide stability and chemical modification strategies have reduced off-target effects and immunogenicity, allowing developers to pursue indications with higher unmet need and greater tolerance for chronic dosing.

Clinical strategy has shifted from proof-of-concept trials toward differentiated product positioning, where safety, durability, and patient-centric delivery become primary differentiators. Subcutaneous administration has grown in prominence because it supports outpatient treatment paradigms and broadens potential prescriber and patient adoption. Meanwhile, the maturation of regulatory guidance for oligonucleotide platforms has clarified requirements for toxicity testing, biomarker validation, and long-term follow-up, which is informing earlier alignment between development teams and regulatory authorities.

Commercially, partnerships between biopharma innovators and specialized contract development and manufacturing organizations are accelerating time-to-clinic, while strategic alliances with diagnostics and digital health providers are enabling more sophisticated patient selection and adherence strategies. These shifts collectively move the field from technology demonstration toward scalable therapeutic programs that are clinically differentiated and commercially viable, prompting stakeholders to reassess manufacturing footprints, patient access strategies, and lifecycle management plans.

Assessment of how tariff policy shifts in 2025 are reshaping sourcing decisions, supply chain resilience, and manufacturing localization strategies for oligonucleotide therapeutics

The policy and trade environment in 2025 has introduced new tariff measures and trade tensions that are ripple factors for complex pharmaceutical value chains, including the ecosystem supporting GalNAc-oligonucleotide conjugates. Tariff adjustments affecting chemical intermediates, specialized reagents, and certain instrumentation can elevate input costs and complicate procurement for developers and contract manufacturers that depend on globally sourced raw materials. These dynamics can increase the administrative burden of international sourcing and prompt procurement teams to re-evaluate supplier risk profiles.

In response, companies are recalibrating supply chain strategies to mitigate exposure to tariff-driven price volatility. Some organizations are diversifying supplier bases across geographies to reduce dependency on any single source or trade corridor. Others are increasing inventory buffers for critical reagents or negotiating long-term contracts to lock in prices and ensure continuity of supply. Simultaneously, nearshoring and regional manufacturing investments are becoming more attractive as a way to insulate production lines from tariff changes and to shorten lead times for clinical and commercial drug supply.

Beyond direct cost impacts, tariffs influence strategic decisions about where to site manufacturing capacity and how to structure distribution networks. For instance, firms may choose to localize higher-value activities such as conjugation and fill-finish closer to end markets, while retaining early-stage synthesis in regions with established scientific capabilities. Regulatory considerations and intellectual property protections also play a role, because intellectual capital-intensive steps are less likely to be relocated if the policy environment increases compliance complexity. Ultimately, tariffs in 2025 are a catalyst for supply chain resilience planning, operational realignment, and closer collaboration between sourcing, legal, and commercial functions to preserve program timelines and control costs without sacrificing quality or regulatory compliance.

Segment-specific analysis linking modality types, therapeutic applications, administration strategies, end users, and distribution choices to commercial and development priorities

Insight into segmentation reveals where scientific opportunity and commercial value intersect across modalities, indications, administration routes, end users, and channels. Based on product type, the field spans antisense oligonucleotides, aptamers, microRNA-targeting molecules, and small interfering RNAs, each bringing different mechanistic attributes, development risks, and clinical positioning considerations. Antisense modalities may offer robust target knockdown with established safety pathways, whereas siRNA constructs frequently leverage GalNAc for highly efficient hepatic silencing, and aptamers present opportunities for precise target engagement with unique pharmacokinetic profiles.

Based on therapeutic application, programs address infectious diseases, metabolic disorders, oncology, and rare diseases, and the indication focus materially influences trial design, biomarker strategy, and payer engagement. Metabolic disorders and rare hepatic conditions often present clear pathways for demonstrating clinical benefit via biomarkers and surrogate endpoints, while oncology and infectious disease applications may demand more complex combination strategies and broader safety surveillance. Based on route of administration, intravenous and subcutaneous delivery routes are both relevant, with subcutaneous administration further differentiated by programs in clinical stage and those that remain in preclinical development; this split affects development timelines, patient acceptance, and outpatient care models.

Based on end user, biotechnology companies, contract research and manufacturing organizations, and pharmaceutical companies drive different parts of the value chain; pharmaceutical companies themselves are further distinguished between large and small organizations with diverse resource profiles and commercialization capabilities. Finally, based on distribution channel, approaches range from direct sales models to distributor-mediated pathways, and each option shapes market access, pricing negotiations, and the complexity of post-market support. These segmentation lenses collectively guide competitive positioning, investment prioritization, and the design of clinical and commercial strategies tailored to modality, indication, and customer type.

Regional dynamics influencing clinical development pathways, manufacturing decisions, and market access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are shaping where innovations in GalNAc-oligonucleotide conjugates progress from discovery to clinic to commercialization. In the Americas, strong venture funding mechanisms, a deep network of biotechnology and contract development capabilities, and an advanced reimbursement framework create an environment conducive to rapid clinical translation and early commercial launches. Clinical trial networks and centers of excellence in hepatic disease enable robust patient recruitment for nuanced endpoints, while partnerships with local manufacturers support scalable supply chains for late-stage programs.

In Europe, the Middle East & Africa, regulatory harmonization among certain jurisdictions, and national systems that prioritize access to novel therapies are influencing clinical development approaches and health technology assessment strategies. European clinical sites often contribute to multi-regional trials that emphasize comparative effectiveness and real-world evidence generation. The Middle East & Africa region presents emerging opportunities for regional manufacturing hubs and market access initiatives, albeit with heterogenous regulatory and reimbursement landscapes that require tailored market entry plans.

In the Asia-Pacific region, a rapidly growing biotech sector, significant manufacturing capacity, and strategic investments in life sciences infrastructure are accelerating both early-stage discovery and commercial production. Regulatory agencies in parts of the region are evolving their frameworks to expedite novel therapeutic approvals, and strong domestic demand for innovative treatments is encouraging partnerships between global developers and regional companies. Across all regions, cross-border collaboration on clinical trials, supply agreements, and regulatory alignment continues to be a decisive factor in determining the pace and scale of product rollouts.

How innovators, pharmaceutical companies, CDMOs, specialty chemistry vendors, and diagnostic partners are organizing collaboratively to accelerate development and commercialization

Companies participating in the GalNAc-oligonucleotide ecosystem are organizing around distinct strategic roles that determine their competitive advantages and growth trajectories. Innovator biotechs are concentrating on proprietary sequences, proprietary conjugation chemistries, and indication-specific clinical strategies, while larger pharmaceutical companies often provide late-stage development expertise, regulatory navigation, global commercialization infrastructure, and scale-up manufacturing capabilities. Contract research organizations and contract development and manufacturing organizations serve as critical enablers, offering specialized synthesis, conjugation services, analytical development, and fill-finish capabilities that de-risk timelines for sponsors.

In parallel, niche technology vendors specialize in linker chemistry, formulation science, and delivery devices that optimize subcutaneous administration and improve patient adherence. Diagnostic and real-world evidence partners provide biomarker assays and longitudinal outcome measurement tools that support both clinical development and payer discussions. Intellectual property holders, academic centers, and translational research hubs continue to feed the pipeline with novel targets and early-stage validation, creating opportunities for licensing and strategic collaborations.

Taken together, the competitive fabric of the ecosystem is characterized by cooperative competition: alliances and licensing agreements are commonplace as companies combine complementary capabilities to accelerate development and broaden commercial reach. Strategic investors and corporate venture groups are actively scouting collaborations to access novel conjugation platforms and differentiated oligonucleotide chemistries, while experienced CDMOs are expanding capabilities to support integrated, end-to-end development journeys from preclinical synthesis to commercial supply.

Concrete operational and strategic steps that industry leaders can implement to de-risk development, optimize supply chains, and accelerate regulatory and commercial readiness

Industry leaders can take practical steps to solidify competitive positioning while reducing operational risk and accelerating time-to-value. First, aligning early with strategic CDMO partners on process transfer, analytical method development, and regulatory expectations can reduce development friction and prevent costly delays during later-stage scale-up. Clear contractual language around quality metrics, change control, and supply continuity is essential to protect clinical and commercial timelines. Second, investing in diversified supplier relationships for critical raw materials, coupled with contingency planning and scenario modeling, will mitigate exposure to trade disruptions and tariff-related cost increases.

Third, companies should prioritize clinical development pathways that demonstrate meaningful patient benefit and favorable safety profiles, using validated biomarkers and pragmatic endpoints where appropriate to support regulatory dialogue and payer value propositions. Fourth, embracing subcutaneous formulations early in development can yield advantages in patient convenience and healthcare system adoption, but it requires concurrent investment in delivery device compatibility and real-world adherence strategies. Fifth, organizations should proactively engage with regulatory authorities across target regions to align on nonclinical requirements, risk management plans, and post-approval evidence generation, thereby reducing uncertainty and streamlining approval pathways.

Finally, commercial readiness requires integrated planning across market access, pricing, and distribution functions. Scenario-based pricing models, early payer engagement, and pilot distribution agreements can accelerate reimbursement discussions and ensure that therapy availability aligns with launch forecasts. By combining operational rigor with strategic foresight, industry leaders can translate scientific promise into durable clinical and commercial outcomes.

Description of the mixed-methods research approach combining expert interviews, scientific literature review, regulatory analysis, and validation to ensure actionable insights

The research behind this analysis combined primary insights from subject matter experts with comprehensive secondary review of peer-reviewed literature, regulatory guidance documents, and public clinical trial registries to construct a rigorous, multi-dimensional perspective. Primary interviews were conducted with stakeholders across the value chain, including medicinal chemists, clinical development leads, manufacturing experts, regulatory consultants, and commercial strategists, to validate trends and surface operational nuances that are not always apparent in public sources. These conversations informed qualitative assessments of supply chain risk, development bottlenecks, and translational science challenges.

Secondary research included systematic review of scientific publications, conference presentations, patent filings, and regulatory communications to ensure the technical narrative accurately reflects recent advances in conjugation chemistry, administration routes, and clinical outcomes. Analytical frameworks applied in the study encompassed value chain mapping, strategic scenario analysis, and a risk-adjusted assessment of operational vulnerabilities such as reagent sourcing and manufacturing localization. Cross-validation techniques were applied by triangulating interview findings, published data, and regulatory signals to strengthen confidence in the conclusions and recommendations.

Limitations of the methodology are acknowledged: rapid technological progress and evolving policy environments can produce new data points after the research window, and proprietary commercial arrangements may not be fully visible through public sources. Nevertheless, the mixed-methods approach provides a robust foundation for strategic decision-making, and the study's iterative validation steps help to minimize bias while highlighting actionable insights for development, manufacturing, and commercialization stakeholders.

Synthesis of key technical advancements, operational imperatives, and strategic priorities that will determine which GalNAc-oligonucleotide programs achieve clinical and commercial success

GalNAc-oligonucleotide conjugates represent a pivotal evolution in targeted nucleic acid therapeutics, marrying receptor-mediated hepatic delivery with molecular precision to address a spectrum of hepatic and systemic conditions. The cumulative effect of improved conjugation chemistry, enhanced oligonucleotide stabilization, evolving clinical trial designs, and a maturing regulatory dialogue positions these modalities for broader therapeutic application. However, translating potential into sustainable commercial success requires intentional operational alignment across supply chain, clinical development, regulatory engagement, and market access functions.

Stakeholders must navigate an environment shaped by tariff dynamics, regional regulatory heterogeneity, and increasing expectations from payers and clinicians for demonstrable, durable benefit. Those organizations that invest in supply chain resilience, prioritize patient-centered administration routes, and secure strategic partnerships across the value chain will be better placed to shorten development timelines and capture clinical and commercial value. In sum, the field is at an inflection point where scientific advances can be rapidly translated into meaningful patient outcomes, provided that development teams pair technical innovation with disciplined execution across manufacturing, regulatory, and commercial dimensions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-Oligonucleotide Conjugates Market, by Product Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. Aptamers
  • 8.3. MiRNA
  • 8.4. SiRNA

9. GalNAc-Oligonucleotide Conjugates Market, by Therapeutic Application

  • 9.1. Infectious Diseases
  • 9.2. Metabolic Disorders
  • 9.3. Oncology
  • 9.4. Rare Diseases

10. GalNAc-Oligonucleotide Conjugates Market, by Route of Administration

  • 10.1. Intravenous
  • 10.2. Subcutaneous
    • 10.2.1. Clinical Stage
    • 10.2.2. Preclinical Stage

11. GalNAc-Oligonucleotide Conjugates Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
    • 11.3.1. Large Pharma
    • 11.3.2. Small Pharma

12. GalNAc-Oligonucleotide Conjugates Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Offline
  • 12.4. Online

13. GalNAc-Oligonucleotide Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. GalNAc-Oligonucleotide Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. GalNAc-Oligonucleotide Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States GalNAc-Oligonucleotide Conjugates Market

17. China GalNAc-Oligonucleotide Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Akcea Therapeutics, Inc.
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Arcturus Therapeutics Holdings Inc.
  • 18.9. Arrowhead Pharmaceuticals, Inc.
  • 18.10. AstraZeneca plc
  • 18.11. Beam Therapeutics Inc.
  • 18.12. BioNTech SE
  • 18.13. CureVac N.V.
  • 18.14. Eli Lilly and Company
  • 18.15. Gilead Sciences, Inc.
  • 18.16. GlaxoSmithKline plc
  • 18.17. Ionis Pharmaceuticals, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Moderna, Inc.
  • 18.20. Novartis AG
  • 18.21. Novo Nordisk A/S
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals, Inc.
  • 18.24. Roche Holding AG
  • 18.25. Sanofi S.A.
  • 18.26. Sarepta Therapeutics, Inc.
  • 18.27. Takeda Development Center Americas, Inc.
  • 18.28. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 177. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)